1. MARTINMUGARPIKE,Ph.D. 11855 SW Murphy Lane
pikema@ohsu.edu 503-593-6428 Beaverton, OR 97008
__________________________________________________________________________________________________
OBJECTIVE
To obtain a challenging position which utilizes my experience and knowledge in disease biology and therapeutics.
SUMMARY OF QUALIFICATIONS
 Extensive knowledge of cancer, stroke, and ischemic heart disease pathophysiology
 Extensive knowledge of cell metabolism, signal transduction, tumor angiogenesis, and cancer therapeutics
 Over 30 years experience in MR imaging/spectroscopy and other modalities
 Comprehensive in vitro and in vivo research experience
 Extensive interactions with pharmaceutical industry
 Long track record in collaborative studies with multiple investigators
 Excellent presentation and proposal writing skills
EDUCATION
Williams College, Williamstown, MA B.A . Chemistry 1978
State University of New York at Stony Brook Ph.D. Chemistry 1985
PROFESSIONAL EXPERIENCE
2007-present Associate Scientist, Advanced Imaging Research Center, Dept of Biomedical Engineering, School of
Medicine, Knight Cancer Institute; Oregon Health & Science University, Portland, OR
 Research program in combinational glioma therapeutics
o development of novel combinational therapeutic anti-angiogenic/anti-tumor strategies
o in vivo mouse intracranial glioma and in vitro cell culture studies
o Principal Investigator of two NIH National Cancer Institute R21 awards
 Collaborative studies with multiple stroke research groups
o MRI measurements of cerebral blood flow, inflammation and edema in animal models of stroke
o investigation of therapeutic neuroprotection strategies
1988-2007 Dept. of Medicine, Division of Cardiovascular Disease, and Department of Cell Biology, University of
Alabama at Birmingham, Birmingham, AL
1995-2007 Associate Professor (with tenure)
1988-1995 Assistant Professor
 Collaboration with the UAB Neuro-oncology program
o Employed novel perfusion MRI methodologies for assessment of tumor vascular properties to
assess efficacy of anti-angiogenic anti-glioma therapeutics.
 Director, 8.5 T Small Animal NMR Facility
o Oversaw facility operations: utilization, promotion, billing, user training, maintenance, upgrades
o Principal Investigator of two major equipment upgrade awards, from NSF and from the UAB HSF
 Research program investigating cardiac ischemia/reperfusion injury.
o Employed novel MRS methodologies to investigate the role of cation and energetic metabolism
o Investigated cardioprotection strategies, employing Na+/H+ exchange inhibition, KATP channel
inhibition and ischemic preconditioning
o Principal investigator: NIH FIRST Award, NIH NHLBI RO1, NIH-NIAAA RO3, American Heart
Association Established Investigator Award, two Alabama American Heart Association grants,
Chugai Pharmaceutical grant.
1985-1988 NIH Postdoctoral Fellow, The Johns Hopkins University School of Medicine, Division of Cardiology,
Baltimore, MD
TEACHING AND LEADERSHIP
 Served as primary advisor for multiple Ph.D. and postdoctoral candidates.
 Served on both NIH NHLBI (Cardiovascular) and NIH NCI (Drug Discovery, Structure, Targeting and
Development) study sections.
 Director, UAB 8.5 T Small Animal NMR Facility, and Chair of OHSU 12T Animal MRI committee
REFERENCES
 Available upon request

2. SELECT PEER REVIEWED PUBLICATIONS
Cancer therapeutics and tumor imaging:
1. Lobo M.R., Green S.C, Schabel M.C., Gillespie G.Y., Woltjer R.L., M.M. Pike; ; Neuro-Oncology 2013 15(12):1673–1683.
Quinacrine Synergistically Enhances the Anti-vascular and Anti-tumor Efficacy of Cediranib in Intracranial Mouse
Glioma
2. Lobo M.R., Wang X., Gillespie G.Y., Woltjer R.L., M.M. Pike; PLoS One, 2014. 9(12): p. e114110. Combined Efficacy of
Cediranib and Quinacrine in Glioma is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
3. Pike M.M., Stoops C.N., Langford C.P., Akella N.S., Nabors L.B., Gillespie G.Y., Magn Res Med 61(3):615-25 (2009); High-
resolution, longitudinal assessment of flow and permeability in mouse glioma vasculature: sequential small molecule
and SPIO dynamic contrast agent MRI;
4. Varallyay C.G., Muldoon L.L., Gahramanov S., Wu Y.J., Goodman J.A., Li X., M. M. Pike., and E. A. Neuwelt; J Cereb Blood
Flow Metab 29(4):853-60, 2009. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of
antiangiogenic versus corticosteroid treatment in a glioma model.
5. Lobo MR, Tran H, Schabel MC, Gillespie G.Y., Woltjer R.L.; Pike M.M.; Synergistic Antivascular and Antitumor Efficacy
with Combined Cediranib and SC6889 in Intracranial Mouse Glioma; (in revision)
Ischemic Heart Disease / Stroke
6. Pike MM, Luo CS, Clark MD, Kirk KA, Kitakaze M, Madden MC, Cragoe EJ, Jr, Pohost GM. Am J Physiol,
265(6Pt2):H2017-H2026, 1993; NMR measurements of Na+ and cellular energy in ischemic rat heart: Role of Na+/H+
exchange.
7. Pike MM, Luo CS, Yanagida S, Hageman GR, Anderson PG. 23Na and 31P. Circ Res, 77(No 2):394-406, 1995. Nuclear
magnetic resonance studies of ischemia-induced ventricular fibrillation: Alterations of intracellular Na+ and cellular
energy
8. Yanagida S, Luo CS, Doyle M, Pohost GM, Pike MM. Circ Res. 1995 Oct;77(4):773-83; Nuclear magnetic resonance
studies of cationic and energetic alterations with oxidant stress in the perfused heart: Modulation with pyruvate and
lactate.
9. Fukuda H, Luo CS, Gu X, Guo L-L, Digerness SB, Li J, Pike MM. J Mol Cell Cardiol 33:545-60, 2001. The effect of KATP
channel activation on myocardial cationic and energetic status during ischemia and reperfusion: Role in
cardioprotection.
10. Takayama E, Guo L-L, Digerness SB, Pike MM. J Mol Cell Cardiol 37(2):483-96, 2004. Early reperfusion levels of Na+
and Ca2+ are strongly associated with postischemic functional recovery but are disassociated from KATP channel-
induced cardioprotection.
11. Nishizawa K, Wolkowicz PE, Yamagishi T, Guo LL, Pike MM. Am J Physiol, Heart Circ Physiol 288(6):H3011-5, 2005.
Fasudil prevents KATP channel-induced improvement in postischemic fuctional recovery
12. G. A West, K J. Golshani, K. P. Doyle, N. S. Lessov, T. R. Hobbs4, S. G. Kohama, M. M. Pike, C.D. Kroenke, M.R. Grafe, M. D.
Spector, E. T. Tobar, R. P. Simon, and M. P. Stenzel-Poore; J Cereb Blood Flow Metab, 2009 Jun;29(6):1175-86 A new
model of cortical stroke in the rhesus macaque.
13. A.A. Ardelt, R.S. Carpenter, M.R. Lobo, H. Zeng, R.B. Solanki, A. Zhang, P. Kulesza, M.M. Pike, , Brain Research (2012),
Jun 21;1461:76-86. Estradiol modulates post-ischemic cerebral vascular remodeling and improves long-term
functional outcome in a rat model of stroke.
14. Siler DA, Berlow YA, Kukino A, Davis CM, Nelson JW, Grafe MR, Ono H, Cetas JS, Pike MM, Alkayed M; Stroke. 2015
Jul;46(7):1916-22. doi: 10.1161/STROKEAHA.114.008560. Epub 2015 May 19; Soluble Epoxide Hydrolase in
Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.
Methodological Development
15. Yanagida S, Luo CS, Balschi JA, Pohost GM, Pike MM. Mag Reson Med 35:640-7, 1996; Simultaneous multicompartment
intracellular Ca2+ measurement in the perfused heart using 19F NMR spectroscopy.
16. Marban E, Kitakaze M, Koretsune Y, Yue DT, Chacko VP, Pike, MM; Circulation Research 1990; 66(5):1255-67. PubMed
[journal] PMID: 2110515; Quantification of [Ca2+]i in perfused hearts. Critical evaluation of the 5F-BAPTA and
nuclear magnetic resonance method as applied to the study of ischemia and reperfusion
17. Marban E, Kitakaze M, Koretsune Y, Yue DT, Chacko VP, Pike MM.; Circulation Research 1988; 63(3):673-8.PubMed
[journal] PMID: 3136952; Ca2+ transients in perfused hearts revealed by gated 19F NMR spectroscopy.
18. Pike, M.M., Simon, S.R., Balschi, J.A., and Springer, C.S., Jr. Proc. Natl. Acad. Sci. USA, 79(3): 810-814, 1982; High
resolution NMR studies of transmembrane cation transport: Use of an aqueous shift reagent for 23Na.
19. Pike, M.M., Fossel, E.T., Smith, T.W., and Springer, C.S., Jr. Am. J. Physiol., 246(5 Pt 1): C528-C536, 1984; High
resolution 23Na NMR studies of human erythrocytes: Use of aqueous shift reagents to allow simultaneous quantitation
of intra- and extracellular sodium.
20. Pike, M.M., Frazer, J.C., Dedrick, D.F., Ingwall, J.S., Allen, P.D., Smith, T.W., and Springer, C.S., Jr. Biophys. J., 48(1):
159-173, 1985; 23Na and 39K NMR studies of perfused, beating, rat hearts: Discrimination of intra- and extracellular
ions using a shift reagent.